Autologous transplantation of P63⁺ lung progenitor cells in patients with bronchiectasis: A randomized, single-blind, controlled trial.

ABSTRACT: Non-cystic fibrosis bronchiectasis is a progressive respiratory disease with limited treatment options, prompting the exploration of regenerative therapies. This study investigates the safety and efficacy of autologous P63⁺ progenitor cell transplantation in a randomized, single-blind, controlled, phase 1/2 trial. Thirty-seven patients receive bronchoscopic airway clearance (B-ACT) (n = 19) or B-ACT plus P63⁺ progenitor cells (n = 18). Results show that compared to the control group, the change in D_LCO levels from baseline to 24 weeks post therapy is significantly higher in the cell treatment group (p value = 0.039). Furthermore, the patients in the cell treatment group demonstrate significantly reduced lung damaged area, improved SGRQ score, and ameliorate

SUBMITTER: Yan J 

PROVIDER: S-EPMC11604513 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature